Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease will be presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

Results from a study examining the ability of an investigational agent to improve endothelial dysfunction, a malfunction in the inner lining of blood vessels, in patients with sickle cell disease will be featured at a press conference on Saturday, December 6, at 9:30 a.m. "Abnormal function of the cells lining blood vessels may contribute to the complications of sickle cell disease. Disruption in the synthesis of nitric oxide, an important regulator of blood vessel relaxation, contributes to these abnormalities," said Nancy Berliner, M.D., 2009 ASH President and Chief of Hematology at Brigham and Women's Hospital in Boston and co-moderator of the press conference on the advances in screening and treatment for sickle cell disease. "This study showcases a novel investigational treatment that aims at improving nitric oxide production and reducing endothelial dysfunction."

Three other late-breaking studies showcasing treatment advances in blood cancers will be highlighted during a press conference on Saturday, December 6, at 2:00 p.m. This press conference will feature the results of a study examining the use of a rituximab-based combination therapy regimen for improving progression-free survival and complete response rates in patients with relapsed or refractory chronic lymphocytic leukemia, the first large-scale study examining mortality rates in patients with cancer taking erythropoiesis-stimulating agents (ESAs) for the treatment of anemia, and the discovery of a new tumor suppressor gene in patients with myeloproliferative disorders.

"There is now additional evidence concerning the use of ESAs in patients with cancer. Last year, ASH col
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... Trust, Inc. (NYSE: BMR ), the ... today announced financial results for the third quarter ... 2014 Highlights Financial and Operating Performance ... representing approximately 657,700 square feet,  contributing to: , ... approximately 219,700 square feet; and , An ...
(Date:10/27/2014)... Oct. 27, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... by a variant of the swine H1N1 virus, known as ... infects nose, throat, and lungs. H1N1 virus is an RNA ... different animal species such as humans, swine, birds, seals, and ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 2BioMed Realty Trust Reports Third Quarter 2014 Financial Results 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 4BioMed Realty Trust Reports Third Quarter 2014 Financial Results 5BioMed Realty Trust Reports Third Quarter 2014 Financial Results 6BioMed Realty Trust Reports Third Quarter 2014 Financial Results 7BioMed Realty Trust Reports Third Quarter 2014 Financial Results 8BioMed Realty Trust Reports Third Quarter 2014 Financial Results 9BioMed Realty Trust Reports Third Quarter 2014 Financial Results 10BioMed Realty Trust Reports Third Quarter 2014 Financial Results 11BioMed Realty Trust Reports Third Quarter 2014 Financial Results 12BioMed Realty Trust Reports Third Quarter 2014 Financial Results 13BioMed Realty Trust Reports Third Quarter 2014 Financial Results 14BioMed Realty Trust Reports Third Quarter 2014 Financial Results 15BioMed Realty Trust Reports Third Quarter 2014 Financial Results 16BioMed Realty Trust Reports Third Quarter 2014 Financial Results 17BioMed Realty Trust Reports Third Quarter 2014 Financial Results 18BioMed Realty Trust Reports Third Quarter 2014 Financial Results 19BioMed Realty Trust Reports Third Quarter 2014 Financial Results 20BioMed Realty Trust Reports Third Quarter 2014 Financial Results 21Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... leader in the development, assembly, marketing and sale of ... the Company will present at the CFA 2012 Cross-Continental ... Purple Mountain Hotel in Shanghai on May 18, 2012. ...
... Medical is pleased to announce that Robert E. Pietrafesa ... Officer. "We,re thrilled to have Rob join ... Belluck, Chairman of the Board at Tegra and General ... Medical. "Tegra is well positioned to serve the growing ...
Cached Medicine Technology:Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2Tegra Medical Announces New President/CEO 2Tegra Medical Announces New President/CEO 3
(Date:10/30/2014)... least 2 years old to be covered by U.S. ... exists other than the general recommendation by national and ... the first six months. , So what do ... motivated researchers at the University at Buffalo School of ... of American infants at 6 months and 12 months ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of sports ... is currently hosting a sweepstakes on its official Facebook ... to U.S. residents age 18 and over, and will ... winner will then be selected at random from all ... NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez views ...
(Date:10/30/2014)... 2014 Don Allred Insurance, a leading ... plans for North Carolina residents, is excited to announce ... Holly Hill Mall. The new branch has been up ... customers through all facets of the insurance selection process ... spokesman Scott Allred couldn’t be happier with the timing ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter ... hormone therapy to men with prostate cancer who also have ... a heart-related cause, a new study suggests. , , The therapy ... in prostate cancer to reduce levels of male hormones to ... And, in the current research, this hormone therapy was linked ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... E taken daily could protect the brain and prevent ... suggests. Scientists in Japan discovered it is possible to ... E. ,They say the supplement is a ... disorders such as Alzheimer's. Taking vitamin supplements could help ...
... According to researchers at the Israel Deaconess Medical Center in ... discover the impact that weight loss can make in decreasing ... people into the first long-term study on how weight loss ... 30 per cent of the population now classified as overweight, ...
... hay fever sufferers. According to a new study in Arizona ... help and not trying to avoid it.// The study has ... as antihistamines with less side effects. ,A team ... gave 120 participants in Arizona and Germany either butterbur extract ...
... have two or more forms of the same chemical ... the isomers, only one generally offers all the therapeutic ... results in smaller dosages with lesser side-effects. ,SUN ... of the anti-ulcerant drug omeprazole - ‘es-omeprazole’ - within ...
... be diagnosed with ovarian cancer every year, and the disease ... percent of all cancers among women. A simple blood test ... stage. Currently, around three-quarters of women with ovarian cancer are ... only about a 20 percent chance// of surviving five years. ...
... that sensible drinking could reduce their risk of suffering a ... a new leaflet, the Stroke Association says small amounts of ... clots blocking arteries - which account for 8 out of ... the blood, so can prevents the formation of clots. It ...
Cached Medicine News:Health News:Herbal treatment not to be sneezed at 2
... IMMULITE 2000 assays ... with the IMMULITE 2000, ... access immunoassay analyzer. IMMULITE ... through centralization, and a ...
... 1000 assays are designed for ... IMMULITE 1000, continuous random access ... in both design and operation. ... in a wide variety of ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
Medicine Products: